Please login to the form below

brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... Padcev is Seattle's second marketed drug after its

Latest news

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Approval comes well ahead of
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

England’s cost effectiveness watchdog says there are limited treatment options for people who have not responded to, or only have a temporary response to, brentuximab vedotin and cannot have stem
Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC
Takeda bags EU approval for Adcetris in lymphoma

CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Route 66: can remote working put two-thirds of us back on the road to engaged employment?: Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals: Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....